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AnalysisCurcumin, the phytochemical agent 
in the spice turmeric that gives 
Indian curry its yellow color and 
distinctive taste, is also a staple of 
traditional Indian medicine (includ-
ing Ayurveda) (see Figure 1). Used 
for millennia as a wound-healing 
agent and for treating a vari-
ety of ailments, the antioxidant 
and anti-inflammatory prop-
erties of curcumin have only 
recently garnered the atten-
tion of researchers interested 
in its mechanisms of action 
and clinicians attracted by its 
therapeutic potential for treat-
ing diseases such as cancer 
and Alzheimer’s disease.
Even as publications on 
curcumin’s effects on cell 
lines and in animal models of 
disease increase dramatically, 
there are only 13 clinical trials 
underway worldwide (see the 
Essay by T.W. Corson and C.M. 
Crews, page 769 of this issue). 
Part of the delay is attributable 
to a US patent, granted in 1995 
to researchers at the University 
of Mississippi Medical Center 
for curcumin’s wound-healing 
properties, that prevented its 
development as a therapeutic. 
In a landmark case, the Indian 
Council of Scientific and Indus-
trial Research (CSIR) spent 
two years arguing and finally 
proving that curcumin has been part 
of the Indian traditional system of 
medicine for centuries and that this 
knowledge should be considered 
“prior art” and hence in the public 
domain. The patent was finally over-
turned in 1997. However, many other 
patents still stand preventing wide-
spread and rigorous development 
of traditional medicines into modern 
therapeutics.
To establish traditional medicines 
as “prior art” and so stem the tide 
of multinational companies rushing 
to patent herbal compounds, the 
Indian government has launched 
an initiative to document and digi-
tize its traditional knowledge. Called 
the Traditional Knowledge Digital 
Library (TKDL), this encyclopedia 
currently contains 24 million pages, 
with more than 120,000 formula-
tions from 100 ancient texts and 
will soon be made available in five 
languages to patent offices world-
wide. “We are currently negotiat-
ing with the patent offices in the 
US, European Union, and Japan to 
make our library accessible to them 
for patent examination,” says Vinod 
Kumar Gupta, the chief architect of 
TKDL and head of information tech-
nology at CSIR in New Delhi. Gupta 
estimates that about 2000 patents 
misappropriating Indian traditional 
resources are granted every year to 
multinational corporations and 
nonresident Indian research-
ers working abroad.
Packaging an Ancient Spice
Overturning the patent on cur-
cumin has only removed some 
hurdles to its development as a 
therapeutic. Given that public 
knowledge does not involve any 
intellectual property (IP), drug 
companies are not interested in 
its commercialization. “Unless 
there is an IP to make money, 
nobody will come forward,” 
says Bharat Bhushan Aggar-
wal, whose research group at 
M.D. Anderson Cancer Center 
in Houston, Texas was the first 
to show that curcumin inhibits 
the master transcription fac-
tor NF-κB that is activated in 
many human tumors (see the 
Essay by Corson and Crews 
on page 769). However, the 
potential benefits of curcumin 
are sufficiently compelling that 
scientists are finding ways to 
overcome the lack of interest 
from big pharma. Although cur-
cumin itself is no longer patentable, 
derivatives, formulations, delivery 
systems, and synthetic methods can 
be patented. For instance, Aggarwal 
founded a company in 2004 called 
Curry Pharmaceuticals that is devel-
oping drugs based on synthetic ana-
logs of curcumin.
Another big hurdle to using cur-
cumin clinically is its insolubility in 
water and hence its poor bioavail-
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Figure 1. A Colorful and Flavorful Medicine
The curry spice turmeric (called haldi in Hindi) contains the 
yellow pigment curcumin, an Indian traditional medicine 
currently being investigated in clinical trials for treating a 
variety of diseases. Turmeric is obtained by grinding the 
roots of the plant Curcuma longa. Photographs courtesy 
of the Indian Institute of Integrative Medicine, Jammu.Cell 130, September 7, 2007 ©2007 Elsevier Inc. 765
ability. For free curcumin to be 
effective as a drug, solubility is cru-
cial so that it can be absorbed by 
the gut and enter the bloodstream. 
But since it is excreted from the gut, 
a patient on curcumin therapy would 
have to take oral doses of 12 to 
20 g, a huge dose given that more 
than 10 g of curcumin leaves an 
almost unbearable aftertaste. Thus, 
scientists are busy developing new 
delivery mechanisms or combina-
tions of curcumin with other com-
pounds to render curcumin more 
suitable for clinical use.
Anirban Maitra at Johns Hop-
kins University School of Medicine 
in Baltimore, Maryland and Ama-
rnath Maitra, a chemistry profes-
sor in India’s Delhi University, have 
developed a “nano” formulation of 
curcumin that is soluble in water. 
They synthesized nanoparticles 
that are hydrophilic on the exterior 
and hydrophobic on the interior and 
then encapsulated curcumin within 
these particles. The hydrophilic 
exterior allows nanocurcumin to be 
soluble in water enabling it to enter 
the bloodstream where the biode-
gradable polymer nanoparticles 
break down. After positive results 
using nanocurcumin to kill pan-
creatic cancer cell lines in the lab, 
Anirban Maitra is ready to move into 
animal models. “These studies are 
aimed at two aspects of cancer—
the treatment of established tumors 
using xenograft models and preven-
tion of cancers in genetically engi-
neered mice,” he says. Meanwhile, 
Anirban Maitra and Johns Hopkins, 
which owns the nanocurcumin pat-
ent, already have the drug industry 
interested in their technology as it 
is easy to produce to GMP (good 
manufacturing practice) require-
ments. “A U.S. pharma company is 
close to licensing our nanocurcumin 
formulation to develop it for multiple 
indications, including Alzheimer’s 
and cancer, and take it to the clinic,” 
says Maitra.
Meanwhile a research group at 
the Indian Institute of Science (IIS) 
in Bangalore has filed a patent 
application for a new combination 
of curcumin and the antimalarial 766 Cell 130, September 7, 2007 ©2007 drug artemisinin, a Chinese tradi-
tional medicine (see the Essay by 
Corson and Crews on page 769). 
The group, supported by India’s 
Department of Biotechnology (DBT) 
in New Delhi, is testing the combi-
nation preclinically and will start 
clinical trials later this year in India, 
which has about 2 million cases of 
malaria annually. Although artemis-
inin combined with other antima-
larial drugs has been used to fight 
resistance of the malaria parasite to 
frontline drugs, most of the combi-
nations are less than ideal because 
of side effects, pharmacokinetic 
mismatches, and cost. Researchers 
at IIS point out that the curcumin-
artemisinin combination may cir-
cumvent some of these problems. 
“Both are from natural sources of 
long-term use and so far no resis-
tance is known to curcumin,” says 
Govindarajan Padmanaban, an 
IIS principal researcher. More-
over, curcumin is tolerated at very 
high doses without any toxic side 
effects, and hence there is potential 
to decrease the dose of artemis-
inin and lower the cost of therapy. 
The problem of poor bioavailability 
can be overcome by adding a low 
dose of piperine (from black pep-
per), which increases the uptake of 
curcumin by 2000% in humans. “We 
have an industry partner, Ipca Labo-
ratories, which will manufacture the 
malaria drugs once the fast-tracked 
human trials are completed,” says 
Padmanaban, who believes India 
will finally have the first “made-in-
India” malaria drug at a much lower 
cost than offered currently by big 
pharma even with special reduced 
price programs.
Taking Traditional Medicines to 
the Clinic
With curcumin once more in the 
public domain, DBT launched eight 
multi-institution clinical trials nation-
wide in 2005 and 2006 to investi-
gate curcumin’s effects on squa-
mous cell carcinoma of the head 
and neck, cervical cancer, oral pre-
malignant cancer, oral fibrosis, and 
clearance of human papillomavirus. 
These multicenter trials involve nine Elsevier Inc.hospitals and research institutions 
across the country, including the All 
India Institute of Medical Sciences 
in New Delhi, Tata Memorial Hospi-
tal in Mumbai, Rajiv Gandhi Center 
for Biotechnology in Thiruvanan-
thapuram, and the National Cancer 
Institute in Kolkata, and are due to 
be completed within two to three 
years. These trials use curcumin for-
mulations that are GMP compliant 
from two Indian companies: Arjuna 
Pharmaceuticals, which makes Bio-
curcumax (95% curcumin in tur-
meric oil), and Sami Labs, which 
makes Bio-prene, a preparation of 
curcumin with piperine.
Touted more as a social service 
for a disease that is expensive to 
treat in developing nations, DBT’s 
large-scale cancer trials anticipate 
no proprietary benefits, but if they 
do see anticancer effects then there 
are plans to “convert the results in a 
nano-based delivery or better com-
binations that could be patented.” 
“Our study primarily aims to show 
to the world that if we test this mol-
ecule in a systematic manner, we 
may provide a cheaper way to treat 
cancer,” says Bindu Dey, director of 
medical biotechnology at DBT. And 
in the hopes of discovering profit-
yielding formulations of curcumin, 
DBT is funding the National Institute 
of Pharmaceutical Education and 
Research in Mohali in northern India 
to research patentable formulations 
of curcumin.
Curcumin’s potential therapeutic 
effects have also garnered inter-
est beyond India’s borders (see 
the Essay by Corson and Crews 
on page 769). Ongoing clinical tri-
als worldwide include investigat-
ing curcumin as a treatment for 
FAP (familial adenomatous polypo-
sis) at Johns Hopkins University in 
Baltimore, chronic psoriasis at the 
University of Pennsylvania, multiple 
myeloma at M.D. Anderson Can-
cer Center in Houston, Texas, and 
pancreatic cancer at Kyoto Univer-
sity in Japan (www.clinicaltrials.
gov). A six month randomized pla-
cebo-controlled double-blind pilot 
clinical trial examining curcumin’s 
effects on Alzheimer’s disease in 
34 patients at the Chinese Univer-
sity of Hong Kong has been com-
pleted. Patients were randomized 
to receive either 4g /day or 1 g/day 
curcumin or placebo. Researchers 
saw no difference in adverse events 
among the three groups. Scores 
on a simple test of cognitive func-
tion (MMSE) did not decline in any 
of the groups including placebo. 
“Interestingly, although the serum 
A-beta peptide level did not differ 
significantly among doses, the level 
did tend to rise in patients treated 
with curcumin, possibly reflecting 
an ability of curcumin to disaggre-
gate A-beta deposits in the brain, 
releasing the A-beta for circulation 
and disposal,” says the trial’s prin-
cipal investigator Lawrence Baum. 
Encouraged by the findings, Baum 
intends to start a larger two-year 
clinical trial with 100–200 Alzheim-
er’s disease patients and using 
a more comprehensive cognitive 
function test (ADAS-Cog) to deter-
mine whether curcumin can slow 
cognitive deterioration.
Getting Back to Basics
As curcumin’s beneficial effects 
are under scrutiny in clinical trials, 
researchers are trying to unravel the 
mechanisms underlying its potent 
antioxidant and anti-inflammatory 
activities. “Curcumin is the most 
effective inhibitor of NF-κB, through 
which it affects several downstream 
targets” including gene products 
involved in blocking apoptosis (Bcl-
2, Bcl-xL, XIAP), invasion (MMP-9), 
angiogenesis (VEGF), and metasta-
sis (adhesion molecules), says M.D. 
Anderson’s Aggarwal.
Meanwhile, biochemist Gau-
risankar Sa at the Bose Institute 
in Kolkata reported this year that 
curcumin’s anti-tumor effects are 
mediated in two ways. “We show 
that curcumin not only boosts the 
immune system in tumor-bearing 
mice by restoring CD4 and CD8 T 
cells, but also increases produc-
tion of proteins that cause immune 
cells to proliferate and reduces the 
production of proteins that destroy 
immune cells.” Administration of 
curcumin to tumor-bearing animals resulted in restoration of progenitor, 
effector, and circulating T cells. “Our 
observations suggest that curcumin 
may be used alone or in combina-
tion with classical anti-tumor drugs 
to sustain the immune capacity of 
the host,” says Sa.
Researchers say that most 
Ayurvedic plants, including curcumin, 
work by modulating the immune 
system through different molecular 
mechanisms. For instance, a polysac-
charide in the Ayurvedic plant Tinos-
pora cordifolia, traditionally used to 
treat throat cancer, induces mitosis of 
B lymphocytes, says Ashok Vaidya, a 
clinical pharmacologist and research 
director of Kasturba Health Society in 
Mumbai. Agents modulating a single 
pathway or cellular target may be less 
effective than a cocktail of botanicals 
to restore immune system homeosta-
sis. But there are limitations. “You can 
derive good immunodrugs from tradi-
tional medicinal plants but you may 
never get a strong analgesic, a cyto-
toxic or a hypolipidemic drug from 
them,” says Bhushan Patwardhan, 
professor and director of the Interdis-
ciplinary School of Health Sciences, 
University of Pune.
Mining Traditional Knowledge
Several scientific measures have 
been taken by the Indian govern-
ment to ensure that drug research-
ers drawing on the Indian traditional 
system of medicine start their inves-
tigation from standardized and safe 
botanical material. “A major scien-
tific shift has been the adoption of 
“reverse pharmacology” for drug 
development from natural prod-
ucts,” says Patwardhan, who also 
leads CSIR’s New Millennium Indian 
Technology Leadership Initiative 
(NMITLI) program on Ayurveda-
based herbal drug development. 
NMITLI was launched in 2002 for 
fast track, innovation-driven indig-
enous development of certain areas 
in science and technology, some 
of which derive from India’s tradi-
tional knowledge. Among the first 
few deliverables of this initiative 
are three new botanicals for arthri-
tis, diabetes, and hepatitis. “The 
usual drug development pathway, Cell 130, Sepfrom laboratory to clinic, is actually 
reversed in the study of traditionally 
used herbal medicines. The strategy 
we are now following is ‘from clin-
ics to laboratories,’” says Patward-
han. In this approach, case studies, 
case series analyses, observational 
studies, including cohort studies, all 
provide data on clinical use and out-
comes of Ayurveda. They also serve 
as clues for mechanisms and thera-
peutic effects of well-established 
herbal drugs.
Researchers say in this process 
safety remains the most important 
starting point and efficacy becomes 
a matter of validation. The process 
also reduces the time and cost of 
development, argues Patwardhan, 
who has four Indian drug compa-
nies as partners in CSIR’s NMITLI 
program as well as several prom-
ising leads. For example, a com-
pound for treating osteoarthritis 
derived from a fully standardized 
polyherbal (a combination of two or 
more plant extracts) is in a phase III 
trial at five Indian centers. “We are 
comparing our compound with the 
largest selling osteoarthritis drugs 
on the market, Glucozamine and 
Celecoxib. While it compares posi-
tively in bioequivalence, our com-
pound shows an added property of 
chondro protection,” says Patward-
han, implying that the new drug can 
prevent degeneration of cartilage 
by protecting the chondrocyte cells 
that build cartilage.
Promising as the polyherbal 
osteoarthritis drug may be, it could 
have a long road to approval in the 
United States. The U.S. Food and 
Drug Administration (FDA) tradition-
ally has been reluctant to approve 
plant extracts or mixtures of differ-
ent compounds. Currently, CSIR is 
building a case before the FDA for 
submission of an Investigational 
New Drug (IND) application for mul-
tiplant extracts. CSIR has a Mem-
orandum of Understanding with 
the FDA-supported National Cen-
ter for Natural Products Research 
(NCNPR) to provide mutual help in 
validating and promoting products 
derived from nature. “The NCNPR 
[and FDA] recognizes the poten-tember 7, 2007 ©2007 Elsevier Inc. 767
tial of more solutions in Ayurveda 
for degenerative disorders and 
hence is keen on multi-plant extract 
research data that we have gener-
ated,” says Ghulam N. Qazi, director 
of the Indian Institute of Integrative 
Medicine in Jammu, who is leading 
the CSIR discussions with the FDA. 
However, there is evidence that the 
FDA may be looking more favor-
ably on polyherbals and botanicals. 768 Cell 130, September 7, 2007 ©2007In November of last year, the FDA 
approved a special extract of green 
tea as a prescription drug for topical 
treatment of genital warts caused 
by human papillomavirus, making it 
the first prescription herbal (botani-
cal) drug approved in the United 
States. Although this approved drug 
is a single plant extract, the FDA 
has received several INDs on mul-
tiplant extracts although none have  Elsevier Inc.yet been approved, says Qazi. The 
CSIR team hopes to file an IND for 
the polyherbal osteoarthritis drug 
before the end of the year.
Although Indian and Chinese tra-
ditional medicine has been used for 
millennia, their recent convergence 
with Western medicine is opening 
up fresh opportunities for develop-
ing new therapeutics and for boost-
ing the effects of existing drugs.
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